A carregar...
Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells
BACKGROUND: The bone-targeting agent zoledronic acid (ZOL) increases breast cancer survival in subsets of patients, but the underlying reasons for this protective effect are unknown. ZOL modulates the activity of osteoclasts and osteoblasts, which form hematopoietic stem cell niches, and therefore m...
Na minha lista:
| Publicado no: | Breast Cancer Res |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5339994/ https://ncbi.nlm.nih.gov/pubmed/28264701 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-017-0815-8 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|